PML related to number of Tysabri infusions, FDA says
This article was originally published in Scrip
Executive Summary
The US FDA has received reports of two further cases of the rare and potentially fatal brain infection, progressive multifocal encephalopathy (PML), in multiple sclerosis patients receiving Biogen Idec's Tysabri (natalizumab), bumping the number of confirmed cases up to 13. However, it is not requiring changes to the drug's label.